An in vitro platform for the rapid and scalable biocatalysis of complex polyketides

Nature has built some of the most sophisticated chemical factories known to science inside tiny bacteria. These microscopic organisms possess long, molecular assembly lines made of protein that can snap together simple building blocks into complex, three-dimensional structures. These structures, known as polyketides, are the source of many life-saving medicines, including antibiotics that fight infection and drugs that calm the immune system. For decades, scientists have dreamed of taking these natural assembly lines out of the bacteria and placing them in a test tube. The idea was to run these molecular machines directly, without the messy interference of a living cell, to create new medicines faster and more cleanly. However, early attempts to do this failed. When researchers tried to run these assembly lines outside the cell, they moved so slowly that the process seemed useless, producing almost nothing before the machinery stopped working.

A team of researchers at The University of Texas at Austin has now overturned this long-held belief. They have developed a new way to run these molecular assembly lines in a test tube that is fast, efficient, and capable of producing large amounts of complex chemicals. By carefully redesigning the protein parts of the assembly line and creating a system that constantly replenishes the fuel the machines need, the team turned a sluggish process into a rapid production line. They demonstrated that these biological machines can work just as fast as the most efficient natural factories found in nature, converting simple ingredients into complex, drug-like molecules in a matter of hours. This breakthrough suggests that scientists can now build libraries of new, complex medicines in a lab setting, bypassing the slow and expensive methods of traditional chemical synthesis or the unpredictable nature of growing bacteria.

The story begins with a specific type of molecular machine called a polyketide synthase. In nature, these machines are like massive conveyor belts made of protein. They take small, simple molecules and link them together in a precise order to build larger, intricate structures. The order of the parts on the belt determines the shape and function of the final product. For years, scientists tried to use these machines inside living bacteria to make medicines. While this worked, it was difficult to control. The bacteria had their own internal processes that competed with the assembly line, and it was hard to tell if a low yield was due to a flaw in the machine or the environment of the cell. Moving the process to a test tube seemed like the logical solution, as it would allow scientists to control every variable. But when they first tried, the machines were incredibly slow. One famous attempt to run a machine that makes an antibiotic called erythromycin showed it moving at a glacial pace, producing only a tiny amount of product before stopping. This led to the widespread assumption that these complex machines simply did not work well outside their natural home.

The researchers set out to prove that this assumption was wrong. They focused on a different machine, one that naturally produces a compound called narbonolide, which is related to the antibiotic pikromycin. Instead of using the natural version of the machine, which is made of four large protein strands, they broke it down into six smaller, more manageable pieces. This refactored design made it easier to produce the machine in the lab and assemble it correctly. They then tested this new setup in a solution containing the necessary fuel and building blocks. Initially, the machine worked, but it was still too slow to be practical, and the product it made was fragile, breaking down in the chemical environment of the test tube. The team realized that the machine was fighting against itself. Some parts of the machine were producing unwanted side products, and the fuel was being wasted.

To fix this, the researchers treated the assembly line like a complex engine that needed tuning. They swapped out specific parts of the machine, replacing generic connectors with ones that fit the specific job better. They moved the labels used to identify the proteins to different spots on the strands to see if it helped the pieces stick together more efficiently. They also added a special cleaning enzyme that acted like a mechanic, removing defective parts that would otherwise jam the assembly line. Each small change made the machine faster. By the time they finished optimizing the design, the machine was working at a speed that was one hundred times faster than the old erythromycin machine and comparable to the speed of the most efficient natural fatty acid factories found in nature. It was no longer a sluggish experiment; it was a high-performance biocatalyst.

The final piece of the puzzle was the fuel system. These machines require a constant supply of energy and specific building blocks to keep moving. In a living cell, the cell provides this fuel automatically. In a test tube, the fuel runs out quickly. The team developed a new platform, which they call the EPK system, that acts as a self-refilling station. This system includes enzymes that constantly regenerate the fuel and the building blocks from simple, cheap ingredients. With this system in place, the researchers could run a reaction in a small beaker for two hours at room temperature. They started with a tiny amount of the machine and simple ingredients, and the machine converted them into a large amount of the final product. In just two hours, they produced enough of the narbonolide compound to fill a small vial, a quantity that would have taken days or weeks to achieve with previous methods.

The success of this platform went beyond just making one compound. The researchers used the same optimized system to build four other complex molecules, each with a slightly different shape. Because the process was so clean and free from the noise of a living cell, they were able to isolate these products in a pure form. This allowed them to determine the exact three-dimensional structure of the molecules using X-ray crystallography, revealing details that had never been seen before. One of the molecules they made had a structure that was a mirror image of a known compound, a subtle difference that is often missed in living cells but was clearly visible here. The ability to produce these complex shapes in pure form opens the door to creating vast libraries of new chemical structures. Scientists can now mix and match different parts of the assembly lines to create thousands of new variations, testing them for medicinal properties without the constraints of growing bacteria.

This work changes the landscape of how complex medicines can be made. It proves that the slowness of these molecular machines was not a fundamental flaw but a result of poor design and a lack of proper support systems. By rebuilding the machines and providing them with a steady stream of fuel, the researchers have unlocked a new way to harness nature's most powerful synthetic tools. The process is now fast enough to be practical and clean enough to produce high-quality materials for drug discovery. While the technology is still in its early stages, the results show that the future of making complex medicines may lie not in growing more bacteria or building more chemical plants, but in refining the molecular assembly lines that nature has already perfected. The door is now open to explore a vast chemical space, creating new possibilities for treating diseases that have long been difficult to reach.